BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koujima T, Tazawa H, Ieda T, Araki H, Fushimi T, Shoji R, Kuroda S, Kikuchi S, Yoshida R, Umeda Y, Teraishi F, Urata Y, Mizuguchi H, Fujiwara T. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Mol Ther Oncolytics 2020;17:107-17. [PMID: 32322667 DOI: 10.1016/j.omto.2020.03.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Luo W, Wang Y, Zhang T. Win or loss? Combination therapy does improve the oncolytic virus therapy to pancreatic cancer. Cancer Cell Int 2022;22:160. [PMID: 35443724 DOI: 10.1186/s12935-022-02583-1] [Reference Citation Analysis]
2 Melgarejo da Rosa M, Clara Sampaio M, Virgínia Cavalcanti Santos R, Sharjeel M, Araújo C, Galdino da Rocha Pitta M, Cristiny Pereira M, Jesus Barreto de Melo Rego M. Unveiling the pathogenesis of perineural invasion from the perspective of neuroactive molecules. Biochem Pharmacol 2021;188:114547. [PMID: 33838132 DOI: 10.1016/j.bcp.2021.114547] [Reference Citation Analysis]
3 Luo W, Zhang T. Current status of minimally invasive surgery for pancreatic cancer. Laparoscopic, Endoscopic and Robotic Surgery 2021. [DOI: 10.1016/j.lers.2021.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Oh CM, Chon HJ, Kim C. Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. Int J Mol Sci 2020;21:E7743. [PMID: 33086754 DOI: 10.3390/ijms21207743] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
5 Tassone E, Muscolini M, van Montfoort N, Hiscott J. Oncolytic virotherapy for pancreatic ductal adenocarcinoma: A glimmer of hope after years of disappointment? Cytokine Growth Factor Rev 2020;56:141-8. [PMID: 32859494 DOI: 10.1016/j.cytogfr.2020.07.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Li Q, Oduro PK, Guo R, Li R, Leng L, Kong X, Wang Q, Yang L. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. Front Cell Infect Microbiol 2022;12:921534. [DOI: 10.3389/fcimb.2022.921534] [Reference Citation Analysis]
7 Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianat-Moghadam H, Ghaemi A. Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. Int Immunopharmacol 2022;108:108882. [PMID: 35623296 DOI: 10.1016/j.intimp.2022.108882] [Reference Citation Analysis]
8 Li J, Kang R, Tang D. Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma. Cancer Commun (Lond) 2021;41:642-60. [PMID: 34264020 DOI: 10.1002/cac2.12188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Seimiya H. Crossroads of telomere biology and anticancer drug discovery. Cancer Sci 2020;111:3089-99. [PMID: 32579791 DOI: 10.1111/cas.14540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]